Weiss Ratings Reiterates “Sell (E+)” Rating for 180 Life Sciences (NASDAQ:ATNF)

180 Life Sciences (NASDAQ:ATNF)‘s stock had its “sell (e+)” rating restated by analysts at Weiss Ratings in a research note issued to investors on Wednesday,Weiss Ratings reports.

180 Life Sciences Stock Performance

NASDAQ:ATNF opened at $0.99 on Wednesday. 180 Life Sciences has a one year low of $0.66 and a one year high of $17.75. The business has a fifty day moving average price of $0.99 and a 200-day moving average price of $1.35.

180 Life Sciences (NASDAQ:ATNF) last posted its quarterly earnings data on Thursday, May 15th. The company reported ($0.67) EPS for the quarter.

Institutional Investors Weigh In On 180 Life Sciences

An institutional investor recently bought a new position in 180 Life Sciences stock. Rathbones Group PLC purchased a new position in 180 Life Sciences Corp. (NASDAQ:ATNF) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 69,995 shares of the company’s stock, valued at approximately $127,000. Rathbones Group PLC owned approximately 2.20% of 180 Life Sciences as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 4.07% of the company’s stock.

About 180 Life Sciences

180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. The company product development platforms includes fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed Phase IIb clinical trials that focuses on fibrosis and anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of non-psychoactive cannabinoids, such as CBD for the treatment of inflammatory diseases and pain; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor.